Recognising and managing antidepressant discontinuation symptoms
Open accessAbstract
Antidepressant discontinuation symptoms occur with all classes of antidepressant. A well-described discontinuation syndrome occurs with the selective serotonin reuptake inhibitors, common symptoms including dizziness, headache, nausea and lethargy. Rare antidepressant discontinuation syndromes include extrapyramidal syndromes and mania/hypomania. All these syndromes, even isolated discontinuation symptoms, share three common features that facilitate diagnosis; abrupt onset within days of stopping the antidepressant, a short duration when untreated and rapid resolution when the antidepressant is reinstated. Clinicians need to be familiar with strategies for the prevention and management of such symptoms. Preventive strategies include warning patients about the possibility of discontinuation symptoms, encouraging good antidepressant adherence and tapering antidepressants at the end of treatment. Most symptoms are mild and short-lived. Consequently symptoms that follow planned termination of an antidepressant can often be managed by providing an explanation and reassurance. More severe symptoms should be treated symptomatically or the antidepressant restarted, in which case symptoms usually resolve within 24 h. More cautious tapering can then follow.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The HAM-D has been criticised for problems in differentiating between withdrawal and depressive symptoms.
“However, this scale has been criticised because of its problems in differentiating between withdrawal and depressive symptoms (Fava 2015: Haddad 2007).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Haddad 2007
The ‘Antidepressant discontinuation symptoms’ and ‘Differential diagnosis’ sections say withdrawal symptoms may be mistaken for recurrent depression and explain how clinicians can distinguish them. They do not mention the HAM-D or criticise its ability to make that distinction. The indexed passages do not specify individual page numbers. (LLM, conf=0.78)
Experimental — accuracy not yet measuredWithdrawal symptoms may be misdiagnosed as relapse when relapse is assessed with the HAM-D scale.
“Withdrawal symptoms may be misdiagnosed as relapse when relapse is assessed with the HAM-D scale (see above, Overall completeness and applicability of evidence) (Fava 2015: Haddad 2007).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Haddad 2007
The ‘Antidepressant discontinuation symptoms’ section says withdrawal symptoms may be diagnosed as relapse or recurrence, and ‘Nature of symptoms’ gives recurrence of depression as an example. The cited paper does not link that risk to assessment with the HAM-D scale. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThe incidence and severity of SSRI withdrawal appears to be influenced by half-life and receptor affinities, duration and dose of usage, method of tapering, and individual patient characteristics.
“The incidence and severity appears to be influenced by half-life and receptor affinities, duration and dose of usage, as well as method of tapering, and individual patient characteristics 3,9 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [3]
The introductory passage (p. 447) identifies half-life, pharmacodynamics and individual patient characteristics as determinants of discontinuation symptoms. The Incidence section (page not available in our copy) links higher doses and longer treatment to more symptoms, but says an effect of abrupt stopping versus tapering has not been demonstrated in clinical studies. The paper does not specifically identify receptor affinities as a factor. (LLM, conf=0.86)
Experimental — accuracy not yet measuredFluoxetine has been routinely identified to cause less severe withdrawal effects than other SSRIs, which has been attributed to its longer half-life.
“It has been routinely identified to cause less severe withdrawal effects than other SSRIs, which has been attributed to its longer half-life 3,30,75 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [3]
The Incidence section (page unavailable) reports that fluoxetine has the lowest incidence of discontinuation symptoms among SSRIs. The Management section (page unavailable) links fluoxetine’s long half-life to its ability to suppress discontinuation symptoms when patients switch from other drugs. Neither passage establishes that symptoms caused by stopping fluoxetine are less severe than those caused by stopping other SSRIs. (LLM, conf=0.86)
Experimental — accuracy not yet measuredThe most common withdrawal symptoms include dizziness, vertigo, tremor, nausea, insomnia, fatigue, mood dysregulation, anxiety, panic, irritability and agitation.
“The most common symptoms include dizziness, vertigo, tremor, nausea, insomnia, fatigue, mood dysregulation, anxiety, panic, irritability and agitation (Fava et al., 2015; Haddad and Anderson, 2007; Jha et al., 2018).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Haddad and Anderson, 2007
The Incidence section’s symptom list includes dizziness, vertigo, tremor, nausea, insomnia, lethargy, low mood, irritability, and anxiety/agitation. But the Primary SSRI discontinuation syndrome section identifies only dizziness, nausea, lethargy, and headache as the most common symptoms; it does not list panic. The citation therefore supports much of the symptom list, but not the claim that all listed symptoms are among the most common. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Withdrawal symptoms can be classified into sensory symptoms, disequilibrium, general somatic symptoms, sleep disturbances, gastrointestinal symptoms and affective symptoms.
“Withdrawal symptoms can be classified into sensory symptoms, disequilibrium, general somatic symptoms, sleep disturbances, gastrointestinal symptoms and affective symptoms (Haddad and Anderson, 2007).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Haddad and Anderson, 2007
The figure reproduced in the Incidence passage lists all six categories, and the ‘Primary SSRI discontinuation syndrome’ section says that syndrome’s symptoms can be divided into six groups. The paper also says symptoms differ between antidepressant classes; its ‘Primary TCA discontinuation syndrome’ section says TCAs share only four of the six groups. The claim omits that SSRI-specific scope. (LLM, conf=0.84)
Experimental — accuracy not yet measuredThe withdrawal syndrome can be differentiated from recurrence of the underlying disorder by its quickness of onset (days rather than weeks), rapid response to re-introduction of the antidepressant (generally within hours, certainly within days), and the presence of somatic and psychological symptoms quite distinct from the original illness.
“However, the withdrawal syndrome can be distinguished from a relapse or recurrence of the underlying disorder by its quickness of onset (days rather than weeks) 3,7,8 , rapid response to re-introduction of the antidepressant (generally within hours, certainly within days) 3,7,9 , and the presence of somatic and psychological symptoms quite distinct from the original illness (including, dizziness,”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [3]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredLonger tapering regimes are required.
“It has generally been concluded from these studies that longer tapering regimes are required 3,33 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [3]
In “Tapering after successful treatment” (page unavailable), the paper says that if tapering SSRIs and venlafaxine reduces symptoms, it may need to last more than 14 days for most patients. But it reports no significant difference between 3- and 14-day tapers and says there are no controlled data establishing an effective taper length. The claim overstates this conditional inference as a general requirement. (LLM, conf=0.88)
Experimental — accuracy not yet measuredAll major antidepressant classes (MAOIs, TCAs, SSRIs, and SNRIs) are associated with a withdrawal syndrome.
“All major classes of antidepressants -MAOIs, TCAs, SSRIs, and SNRIs -are associated with withdrawal symptoms 2,3 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [3]
There are individual differences in each person's experience of SSRI withdrawal effects.
“There is likely to be individual differences in each person's experience of SSRI withdrawal effects 3 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [3]
Antidepressant withdrawal reactions can be mistaken for relapse of the underlying condition.
“It has also been noted in several reviews of antidepressant withdrawal symptoms that such reactions can be mistaken for relapse of the underlying condition for which the antidepressant was originally prescribed,18–20”
The issue of relapse being mistaken for withdrawal symptoms has been a long-running concern among experts.
“The issue of ‘relapse’ being mistaken for withdrawal symptoms has been a long-running issue of concern amongst experts,18 including the DSM-5 explicitly warning about this possibility.21”
Symptoms are most commonly reported after sudden cessation of the medication, but can also occur following gradual tapering of the dose.
“Symptoms are most commonly reported after sudden cessation of the medication, but can also occur following gradual tapering of the dose [4].”
From SSRI and SNRI withdrawal symptoms reported on an internet forum (2018) · cites this paper as [4]
Onset of withdrawal symptoms after a week is considered unusual.
“Onset of withdrawal symptoms after a week is considered unusual [4].”
From SSRI and SNRI withdrawal symptoms reported on an internet forum (2018) · cites this paper as [4]
There is clear evidence that a variety of symptoms can result from discontinuation of all antidepressant classes.
“There is now clear evidence that a variety of symptoms can result from the discontinuation of all antidepressant classes [4].”
From SSRI and SNRI withdrawal symptoms reported on an internet forum (2018) · cites this paper as [4]
The prominence of psychological, neurological and gastrointestinal symptoms is consistent with previous literature on SSRI and SNRI withdrawal, lending the study face validity.
“The prominence of psychological, neurological and gastrointestinal symptoms is consistent with the previous literature on SSRI and SNRI withdrawal [4], and lends this study face validity.”
From SSRI and SNRI withdrawal symptoms reported on an internet forum (2018) · cites this paper as [4]
The narratives analyzed in this study indicate that consumers are able to distinguish drug withdrawal from the symptoms of the original illness, because withdrawal symptoms are experienced as more intense, urgent, and often unprecedented, that is, qualitatively different.
“The narratives analyzed in this study likewise indicate that consumers are able to distinguish drug withdrawal from the symptoms of the original illness, since withdrawal symptoms are experienced as more intense, urgent, and often unprecedented, that is, qualitatively different.28,30,35”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355 · see citing works
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · see citing works
Anderson, I. M., Ferrier, I. N., Baldwin, R., Cowen, P. J., Howard, L. M., Lewis, G., Matthews, K., McAllister-Williams, H., Peveler, R. C., Scott, J. L., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 901 · see citing works
Self-citationSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · see citing works
Laine, K., Heikkinen, T., Ekblad, U., & Kero, P. O. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.720 · Cited by 329 · see citing works
COMMITTEE ON SAFETY OF MEDICINES
Scowen, E. F. (1978) · British Journal of Anaesthesia · doi:10.1093/bja/50.12.1270-a · Cited by 296 · see citing works
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207 · see citing works
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
D, M. F. M., Mulroy, R., Alpert, J. E., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198 · see citing works
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · see citing works
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171 · see citing works
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
Bymaster, F. P., Rasmussen, K. G., Calligaro, D. O., NELSON, D. A., DeLapp, N. W., Wong, D. T., & Moore, N. A. (1997) · PubMed · Cited by 162 · see citing works
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140 · see citing works
The SSRI discontinuation syndrome
Haddad, P. M. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200311 · Cited by 123 · see citing works
Self-citationTint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107081550 · Cited by 114 · see citing works
Self-citationWITHDRAWAL SYMPTOMS FOLLOWING DISCONTINUATION OF IMIPRAMINE THERAPY
KRAMER, J. C., KLEIN, D. F., & FINK, M. (1961) · American Journal of Psychiatry · doi:10.1176/ajp.118.6.549 · Cited by 113 · see citing works
Hypomania and mania after withdrawal of tricyclic antidepressants
Mirin, S. M., Schatzberg, A. F., & Creasey, D. E. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.1.87 · Cited by 95 · see citing works
The Antidepressant Web: Marketing depression and making medicines work
Medawar, C. (1997) · International Journal of Risk and Safety in Medicine · doi:10.3233/jrs-1997-10203 · Cited by 92 · see citing works
Do antidepressants have any potential to cause addiction?
Haddad, P. M. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300321 · Cited by 89 · see citing works
Self-citationDiscontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00002 · Cited by 87 · see citing works
David, P., Kajdasz, D. K., Desaiah, D., & Haddad, P. M. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.09.003 · Cited by 86 · see citing works
Self-citationBogetto, F., Bellino, S., Revello, R. B., & Patria, L. (2002) · CNS Drugs · doi:10.2165/00023210-200216040-00006 · Cited by 80 · see citing works
Schatzberg, A. F., Blier, P., Delgado, P. L., D, M. F. M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 78 · see citing works
Self-citationAntidepressant Withdrawal Syndromes
Dilsaver, S. C., Kronfol, Z., Sackellares, J. C., & Greden, J. F. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198306000-00003 · Cited by 77 · see citing works
TOFRANIL‐TREATMENT OF ENDOGENOUS DEPRESSIONS
Andersen, H., & Kristiansen, E. S. (1959) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1959.tb07529.x · Cited by 74 · see citing works
Weller, I. V. D., Ashby, D., Brook, R., Mga., C., Chick, J., Drummond, C., Ebmeier, K. P., Gunnell, D., Hawking, H., Mukaetova‐Ladinska, E. B., et al. (2005) · Cited by 74 · see citing works
Neonatal convulsions caused by withdrawal from maternal clomipramine.
Cowe, L., Lloyd, D. J., & Dawling, S. (1982) · BMJ · doi:10.1136/bmj.284.6332.1837-a · Cited by 72 · see citing works
Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 69 · see citing works
Self-citationAntidepressant withdrawal symptoms treated with anticholinergic agents
Dilsaver, S. C., Feinberg, M. P., & Greden, J. F. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.2.249 · Cited by 67 · see citing works
Goldstein, T. R., Frye, M. A., Denicoff, K. D., Smith‐Jackson, E. E., Leverich, G. S., Bryan, A. L., Ali, O., & Post, R. M. (1999) · PubMed · Cited by 64 · see citing works
Suspected congenital sertraline dependence
Kent, L., & Laidlaw, J. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.3.412b · Cited by 64 · see citing works
Antidepressant Withdrawal Syndromes
Dilsaver, S. C., & Greden, J. F. (1983) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198310000-00031 · Cited by 62 · see citing works
Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine
Demyttenaere, K., Mesters, P., Boulanger, B., Dewé, W., Delsemme, M.-H., Grégoire, J. C., & Ganse, E. H. V. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00225-1 · Cited by 61 · see citing works
Fluvoxamine withdrawal syndrome
Szabadi, E. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.160.2.283b · Cited by 58 · see citing works
Adverse events after the abrupt discontinuation of paroxetine
Dominguez, R. A., & Goodnick, P. J. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb02896.x · Cited by 57 · see citing works
Clinical Experience with Imipramine (G 22355) in the Treatment of Depression
Mann, A. M., & Macpherson, A. S. (1959) · Canadian Psychiatric Association Journal · doi:10.1177/070674375900400111 · Cited by 57 · see citing works
Extrapyramidal symptoms upon discontinuation of fluoxetine
Stoukides, J., & Stoukides, C. A. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.9.1263a · Cited by 57 · see citing works
Tyrer, P. J. (1984) · Journal of Affective Disorders · doi:10.1016/0165-0327(84)90002-8 · Cited by 54 · see citing works
Medication Withdrawal Symptoms in Obsessive-Compulsive Disorder Patients Treated with Paroxetine
Keuthen, N. J., Cyr, P., Ricciardi, J. A., Minichiello, W. E., Buttolph, M. L., & Jenike, M. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00010 · Cited by 53 · see citing works
Haddad, P. M., Pal, B. R., Clarke, P., Wieck, A., & Sridhiran, S. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056554 · Cited by 51 · see citing works
Self-citationShock-like sensations after discontinuation of selective serotonin reuptake inhibitors
Frost, L., & Lal, S. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.5.810a · Cited by 49 · see citing works
Severe psychiatric symptoms associated with paroxetine withdrawal
Bloch, M., Stager, S., Braun, A., & Rubinow, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92691-7 · Cited by 45 · see citing works
Imipramine Withdrawal: An Akathisia-Like Syndrome
Sathananthan, G., & Gershon, S. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.11.1286 · Cited by 35 · see citing works
Hypomania after desipramine withdrawal
Nelson, J. C., Schottenfeld, R. S., & Conrad, C. D. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.5.624 · Cited by 35 · see citing works
Antidepressant withdrawal reactions.
Wolfe, R. (1997) · PubMed · Cited by 34 · see citing works
Intractable Withdrawal From Venlafaxine Treated With Fluoxetine
Giakas, W. J., & Davis, J. M. (1997) · Psychiatric Annals · doi:10.3928/0048-5713-19970201-05 · Cited by 33 · see citing works
Venlafaxine withdrawal reactions
Louie, A. K., Lannon, R. A., Kirsch, M. A., & Lewis, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1652a · Cited by 33 · see citing works
A possible paroxetine withdrawal syndrome
Phillips, S. D. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.645b · Cited by 32 · see citing works
Venlafaxine Withdrawal Symptoms
Benazzi, F. (1996) · The Canadian Journal of Psychiatry · doi:10.1177/070674379604100722 · Cited by 26 · see citing works
Antidepressant discontinuation (withdrawal) symptoms presenting as ‘stroke’
Haddad, P. M., Devarajan, S., & Dursun, S. M. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500210 · Cited by 25 · see citing works
Self-citationMirtazapine withdrawal causing hypomania
MacCall, C. A., & Callender, J. S. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.4.390a · Cited by 24 · see citing works
Tranylcypromine withdrawal phenomena.
Halle, M. T., & Dilsaver, S. C. (1993) · PubMed · Cited by 22 · see citing works
Acute Psychosis Following Phenelzine Discontinuation
LISKIN, B., Roose, S. P., Walsh, B. T., et al. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198502000-00010 · Cited by 22 · see citing works
More cases of paroxetine withdrawal syndrome
Pacheco, L., Malo, P., Aragues, E., & Etxebeste, M. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.3.384a · Cited by 21 · see citing works
Acute psychosis following phenelzine discontinuation.
LISKIN, B., Roose, S. P., Walsh, B. T., & Jackson, W. (1985) · PubMed · Cited by 20 · see citing works
Do antidepressants cause dependence?
Haddad, P. M. (2005) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00006254 · Cited by 20 · see citing works
Self-citationMania After Withdrawal of Isocarboxazid
Rothschild, A. J. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198512000-00007 · Cited by 20 · see citing works
Withdrawing patients from antidepressants
(1999) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.1999.37749 · Cited by 19 · see citing works
Paroxetine induced withdrawal effects
Koopowitz, L. F., & Berk, M. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100210 · Cited by 18 · see citing works
Misdiagnosis of antidepressant discontinuation symptoms
Haddad, P. M., & Qureshi, M. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102006466.x · Cited by 16 · see citing works
Self-citationVandel, P., Sechter, D., Weiller, E., Pezous, N., Cabanac, F., Tournoux, A., & Panconi, E. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.644 · Cited by 15 · see citing works
Orthostatic hypotension induced by sertraline withdrawal
Amsden, G. W., & Georgian, F. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb03653.x · Cited by 14 · see citing works
Mania After Withdrawal of Isocarboxazid
Rothschild, A. J. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198505060-00007 · Cited by 13 · see citing works
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13 · see citing works
Self-citationRestlessness related to SSRI withdrawal
Hirose, S. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00789.x · Cited by 10 · see citing works
Antidepressants aren't addictive: clinicians have depended on them for years
Haddad, P. M., & Anderson, I. M. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300313 · Cited by 9 · see citing works
Self-citationStress diathesis and pharmacological dependence
Tyrer, P. J. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300316 · Cited by 4 · see citing works
Benazzi, F. (1999) · PubMed · Cited by 4 · see citing works
Pharmacists Lack Knowledge of Antidepressant Discontinuation Symptoms
Donoghue, J., & Haddad, P. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0210e · Cited by 3 · see citing works
Self-citationRojas‐Fernandez, C. H., & Gordon, J. (1998) · PubMed · Cited by 3 · see citing works
&NA; (1996) · Reactions Weekly · doi:10.2165/00128415-199605960-00024 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 7
- [24]24. Goldstein, T. R., Frye, M. A., Denicoff, K. D., et al (1999) Anti depressant discontinuationrelated mania: critical prospective observation and theoretical implications in bipolar disorder. Journal of Clinical Psychiatry, 60, 563-67
- [30]30. Haddad, P., Tylee, A. & Young, A. P. (1999) General practitioners' knowledge of antidepressant discontinuation reactions (abstract). Journal of Psychopharmacology, 13 (suppl. A), A44.
- [53]53. Price, J. S., Waller, P. C., Wood, S. M., et al (1996) A comparison of the postmarketing safety of four selective serotonin reuptake inhibitors, including the investigation of symptoms occurring on withdrawal. British Journal of Clinical Pharmacology, 42, 757-763.
- [55]55. Roth, S. D. (1985) More on psychosis following phenelzine discon tinuation. Journal of Clinical Psychopharmacology, 5, 360-361.
- [57]57. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al (2006) BupropionSR, sertraline, or venlafaxineXR after failure of SSRIs for depression. New England Journal of Medicine, 354, 1231-1242.
- [58]58. Sathananthan, G. L. & Gershon, S. (1973) Imipramine withdrawal: an akathisialike syndrome. American Journal of Psychiatry, 130, 1286-87
- [69]69. Young, A. H. & Currie, A. (1997) Physicians' knowledge of antidepressant withdrawal effects: a survey. Journal of Clinical Psychiatry, 58 (suppl. 7), 28-30.
Cited by
Sorted by citations
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · see citing works
“Amongst the antidepressants, discontinuation symptoms are more likely with venlafaxine (Haddad and Anderson, 2007; Tint et al., 2008) and short-acting SSRIs (especially paroxetine), but less likely with fluoxetine (Michelson et al.”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · see citing works
Self-citationMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614 · see citing works
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387 · see citing works
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · see citing works
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107 · see citing works
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103 · see citing works
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90 · see citing works
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77 · see citing works
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76 · see citing works
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74 · see citing works
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72 · see citing works
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63 · see citing works
Huijbers, M. J., Spinhoven, P., Spijker, J., Ruhé, H. G., van Schaik, D. J. F., van Oppen, P., Nolen, W. A., Ormel, J., Kuyken, W., van der Wilt, G. J., et al. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.168971 · Cited by 58 · see citing works
SSRI and SNRI withdrawal symptoms reported on an internet forum
Stockmann, T., Odegbaro, D., Timimi, S., & Moncrieff, J. (2018) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-180018 · Cited by 54 · see citing works
Mechanisms of SSRI Therapy and Discontinuation
Sharp, T., & Collins, H. (2023) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2023_452 · Cited by 45 · see citing works
Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000100 · Cited by 30 · see citing works
Jauhar, S., & Hayes, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.01.025 · Cited by 23 · see citing works
La, M. K., Thompson Bastin, M. L., Gisewhite, J. T., Johnson, C. A., & Flannery, A. H. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.07.046 · Cited by 17 · see citing works
Rennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8 · see citing works
“Withdrawal symptoms can be classified into sensory symptoms, disequilibrium, general somatic symptoms, sleep disturbances, gastrointestinal symptoms and affective symptoms (Haddad and Anderson, 2007).”
Do discontinuation symptoms predict depression relapse after antidepressant cessation?
Volkmann, C., Abulikemu, S., Berwian, I. M., Huys, Q. J., & Walter, H. (2023) · doi:10.31234/osf.io/fxye5 · Cited by 2 · see citing works
- Authors
- Haddad, P. M., & Anderson, I. M.
- Corresponding author
- Haddad, Peter M.
- Venue
- Advances in Psychiatric Treatment
- Publisher
- Cambridge University Press (CUP)
- Published
- 2007-11
- Volume
- 13
- Issue
- 6
- Pages
- 447-457
- ISSN
- 1355-5146 (ISSN-L)
- 1472-1481
- OpenAlex
- W2166325964
- Cited by
- 109
- References
- 71
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 11 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 14 · 2019: 3 · 2018: 7 · 2017: 7 · 2016: 6 · 2015: 8 · 2014: 6 · 2013: 7 · 2012: 3
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Advances in Psychiatric Treatment (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- antidepressant discontinuation syndrome, selective serotonin reuptake inhibitors, extrapyramidal symptoms, mania, hypomania, antidepressant tapering, antidepressant adherence, symptom management, dizziness, headache, nausea, lethargy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
